Department of Medicine, Division of Neurology, Duke University Medical Center, DUMC 3403, Durham, North Carolina 27710, USA.
Muscle Nerve. 2012 Mar;45(3):363-6. doi: 10.1002/mus.22327.
In this study we estimated the costs paid by U.S. health plans for treating myasthenia gravis (MG) in 2009 and determined the major cost drivers.
One hundred thirteen MG patients were matched by propensity scores with 339 non-MG patients from a comprehensive health-care insurance database. The mean annual costs paid by the health plan for treating MG, costs by place of service, and costs for intravenous immunoglobulin (IVIg) and plasma exchange were determined.
Mean annual costs paid by the health plan per MG patient were $20,190 (SEM $4,763) and costs attributable to treating MG were $15,675. Home health services accounted for 23% of MG patient costs and represented almost exclusively IVIg infusion costs. Six MG patients had a total of 136 outpatient IVIg infusions at an average annual cost of $109,463 ± $57,303.
The estimated annual health plan paid costs for treating MG were $15,675. Home health services represented 23% of MG patient costs, largely driven by IVIg administration.
本研究旨在估计美国健康计划在 2009 年治疗重症肌无力 (MG) 的费用，并确定主要的成本驱动因素。
从一个综合性医疗保险数据库中，通过倾向评分匹配了 113 名 MG 患者和 339 名非 MG 患者。确定了健康计划为治疗 MG 支付的年平均费用、按服务地点划分的费用，以及静脉注射免疫球蛋白 (IVIg) 和血浆置换的费用。
健康计划为每名 MG 患者支付的年平均费用为 20190 美元（SEM 为 4763 美元），归因于治疗 MG 的费用为 15675 美元。家庭保健服务占 MG 患者费用的 23%，且几乎完全由 IVIg 输注费用构成。6 名 MG 患者共进行了 136 次门诊 IVIg 输注，年平均费用为 109463 美元 ± 57303 美元。
估计治疗 MG 的健康计划年支付费用为 15675 美元。家庭保健服务占 MG 患者费用的 23%，主要由 IVIg 给药驱动。
